Back to Investors
Investment Case
A diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology Manufacturers, Uniphar represents a strong combination of scale, growth and profitability.
In 2019, the Group generated revenue of €1.67 billion, gross profit of €180.6 million and EBITDA of €58.6 million (after the impact of IFRS 16). With a workforce of more than 2,200, the Group is active in Ireland, UK, Benelux, Nordics and USA.
2019 Preliminary Results
2019 Preliminary Key Stats
€58.6m
EBITDA (Post IFRS-16)
7%
Organic GP Growth YoY
14.7%
ROCE 2019
14.3c
Adjusted EPS
Group Highlights
€180.6m
2019 GP
Employees
Partnering with 7 of the top 10 pharma companies
and 6 of the top 10 medical device companies
